Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

BVES-HA IP-mass from AAV9-BVES-HA injected mouse skeletal muscle

ABSTRACT: To identify BVES-interacting proteins from mouse skeletal muscle, we performed IP-mass from AAV9-BVES-HA injected mouse skeletal muscle using the anti-HA magnetic beads.

INSTRUMENT(S):

ORGANISM(S): Mus Musculus (mouse)

SUBMITTER: Haiwen Li

LAB HEAD: Renzhi Han

PROVIDER: PXD036346 | Pride | 2023-02-27

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	CTRL.dat	Other
	CTRL.mgf	Mgf
	CTRL.mzid	Mzid
	CTRL.raw	Raw
	KO.dat	Other

Items per page:

1 - 5 of 9

Similar Datasets

Identification of FoxO target genes during C-26 cancer cachexia

Project description:Forkhead BoxO (FoxO) transcription factors expressed in adult skeletal muscle promote muscle atrophy during various catabolic conditions. We have identified the genome wide target genes and biological networks regulated by FoxO in skeletal muscle during Colon-26 (C-26) cancer cachexia. In this dataset, we include the expression data obtained from the tibialis anterior muscles of control and severely cachectic Colon-26 mice in which FoxO-dependent transcription was either intact (AAV9-EV) or inhibited (AAV9-d.n.FoxO). These data were used to obtain 543 FoxO target genes during cancer. These target genes were identified as those genes whose expression was both differentially regulated in skeletal muscle in response to cancer (control AAV9-EV vs. C26 AAV9-EV), and differentially regulated in the presence of d.n.FoxO (C26 AAV9-EV vs. C26 AAV9-d.n.FoxO).

2014-12-31 | GSE56555 | GEO

Labyrinthula sp. Ha isolate:Ha

Project description:Labyrinthula sp. Ha isolate:Ha Genome sequencing and assembly

| PRJNA607370 | ENA

Acinetobacter sp. HA strain:HA

Project description:Acinetobacter sp. HA strain:HA Genome sequencing and assembly

| PRJNA158435 | ENA

miRNA array in the A549 Ago2-KO/HA-Ago2Wt, Ago2-KO/HA-Ago2KA, and Ago2-KO/HA-Ago2Δ (Dm) cells

Project description:We used miRNA microarrays to detail the miRNA content in A549 Ago2-KO/HA-Ago2Wt, Ago2-KO/HA-Ago2KA, and Ago2-KO/HA-Ago2Δ (Dm) cells

2024-04-18 | GSE255941 | GEO

HA-TFE3 bound regions in HK-2 HA-TFE3-inducible cells

Project description:TFE3 is a bHLH-ZIP transcription factor, which nuclear localization is regulated by a tumor suppressor FLCN. In order to analyze TFE3 occupancy in whole genome, we have generated and utilized a HK-2 HA-TFE3-inducible cell line which express HA-tagged TFE3 in a doxycycline-dependent manner. HA-TFE3 bound regions were determined by ChIPSeq.

2020-08-07 | GSE135490 | GEO

HA-PSF-TFE3 bound regions in HA-PSF-TFE3 inducible HK-2 cells

Project description:PSF-TFE3 is an oncogenic chimeric transcription factor derived from human TFE3-rearranged renal cell carcinoma. To analyze its genome-wide occupancy, we developed HA-tagged PSF-TFE3-inducible HK-2 cell lines, which expresses HA-tagged PSF-TFE3 in a doxycycline-dependent manner. We determined the binding regions of HA-PSF-TFE3 by ChIPSeq.

2025-08-18 | GSE297289 | GEO

HA-PRCC-TFE3 bound regions in HA-PRCC-TFE3 inducible HK-2 cells

Project description:PRCC-TFE3 is an oncogenic chimeric transcription factor derived from human TFE3-rearranged renal cell carcinoma. To analyze its genome-wide occupancy, we developed HA-tagged PRCC-TFE3-inducible HK-2 cell lines, which expresses HA-tagged TFE3 in a doxycycline-dependent manner. We determined the binding regions of HA-PRCC-TFE3 by ChIPSeq.

2025-01-22 | GSE281281 | GEO

Trial of FOLF(HA)Iri With Cetuximab in mCRC

Project description:As an approach to improve efficacy and provide clinical benefit to cancer patients undergoing chemotherapeutic treatment regimens, Alchemia Oncology has developed a novel means for delivering anti-cancer agents to tumours. The drug delivery platform is based on the use of hyaluronic acid (HA), a novel excipient, in which, formulation with HA results in optimisation of cytotoxic drug uptake and retention within solid tumours. In the specific example of HA-Irinotecan, this new formulation of irinotecan has demonstrated enhanced efficacy in both nonclinical and early clinical studies. The current study is an investigation into the use of HA-Irinotecan in a Phase II single arm trial of FOLF(HA)iri plus cetuximab in irinotecan-naïve second line patients with KRAS wild type metastatic colorectal cancer. The study objectives are to confirm the safety and efficacy of FOLF(HA)iri plus cetuximab as second-line therapy in irinotecan-naïve metastatic colorectal cancer patients. It is expected that the study recruit approximately 40-50 patients in 1 year with subsequent treatment and follow up; thus the trial will run for approximately 2-3 years.

| 2172573 | ecrin-mdr-crc

Aeromicrobium sp. HA

Project description:Aeromicrobium sp. HA Assembly

| PRJNA911185 | ENA

RNA binding properties of PDHA2, TEX30 in testis; RNA binding properties of HA-NONO and HA-NONO△ER in 3T3L1 cell line.

Project description:To investigate the RNA binding proterties of PDHA2, TEX30 in testis; RNA binding properties of HA-NONO and HA-NONO△ER in 3T3L1 cell line, we collected wildtype testis and HA-NONO/HA-NONO△ER overexpressed 3T3L1 cells. We then performed eCLIP-seq respectively and convey subsequent bioinformatic analysis.

2024-08-08 | GSE232595 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data